CEO and Co-Founder, Visikol
BIOGRAPHY
MAR 25, 2021 8:00 AM PDT
Aperio VERSA - Visikol's Highly Multiplexed Immunohistochemistry Approach to Drug Discovery
Speaker
Event Date & Time
Date: March 25, 2021
Time: 8:00am (PDT), 11:00am (EDT)
Abstract
Visikol is a biotechnology company focused on advanced imaging, digital pathology and 3D cell culture assays that has developed a unique imaging platform that allows for 10+ plex immunofluorescent slide imaging. Through this presentation, Visikol will provide a background on various multiplex tissue imaging approaches and will describe how they can be used to answer complex research questions such as surveying the immune cell population within a tumor microenvironment or evaluating therapeutics for infectious diseases. Specifically, Visikol will discuss how its proprietary multiplex approach has been leveraged through a partnership with Hackensack Meridian Health (HMH) to evaluate tuberculosis treatments. This work is funded by the Bill & Melinda Gates Foundation using Visikol's multiplex approach combined with several other imaging modalities to evaluate treatments using a multi-modal imaging approach.
Learning Objectives
- Develop an understanding of multiplex slide labeling and imaging techniques.
- Demonstrate a working knowledge of the multiple types of multiplex tools available for whole slide imaging.
- Identify the unique types of research questions that can be addressed through multiplex imaging.
Webinars will be available for unlimited on-demand viewing after live event.
For Research Use Only. Not for Use in Diagnostic Procedures
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
Loading Comments...